Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial-Reference-Cited by-同舟云学术

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

Published:2007-12-10 Issue:1 Volume:47 Page:43-50
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Mangia Alessandra,Minerva Nicola,Bacca Donato,Cozzolongo Raffaele,Ricci Giovanni L.,Carretta Vito,Vinelli Francesco,Scotto Gaetano,Montalto Giuseppe,Romano Mario,Cristofaro Giuseppe,Mottola Leonardo,Spirito Fulvio,Andriulli Angelo

Publisher

Wiley

Subject

Hepatology

Reference25 articles.

1. NIH Consensus Development Statement on Management of Hepatitis C: 2002;HEPATOLOGY,2002

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

3. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial;Manns;Lancet,2001

4. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose;Hadziyannis;Ann Intern Med,2004

5. Early virologic response to treatment with peginterferon alfa-2 plus ribavirin in patients with chronic hepatitis C;Davis;HEPATOLOGY,2003

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostics in hepatitis C: The end of response-guided therapy?;Journal of Hepatology;2016-10

2. The Role of Pathological Staging in Selection of Appropriate Treatment Option for Autoimmune Hepatitis: Findings of a Prospective Observational Study;INT J PEDIATR-MASSHA;2016

3. KASL clinical practice guidelines: management of hepatitis C;Clinical and Molecular Hepatology;2016-03-28

4. Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy;Antiviral Research;2016-02

5. Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C;Journal of Postgraduate Medicine;2016